UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.81 Million Stake in Certara, Inc. (NASDAQ:CERT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 263,574 shares of the company's stock after purchasing an additional 37,870 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of Certara worth $2,807,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Voloridge Investment Management LLC grew its position in Certara by 269.3% in the 4th quarter. Voloridge Investment Management LLC now owns 275,633 shares of the company's stock valued at $2,935,000 after buying an additional 201,003 shares in the last quarter. Squarepoint Ops LLC raised its position in shares of Certara by 62.7% during the 4th quarter. Squarepoint Ops LLC now owns 94,433 shares of the company's stock worth $1,006,000 after buying an additional 36,386 shares in the last quarter. Two Sigma Advisers LP lifted its stake in shares of Certara by 35.7% in the 4th quarter. Two Sigma Advisers LP now owns 87,500 shares of the company's stock worth $932,000 after acquiring an additional 23,000 shares during the period. Two Sigma Investments LP lifted its stake in shares of Certara by 20.1% in the 4th quarter. Two Sigma Investments LP now owns 377,524 shares of the company's stock worth $4,021,000 after acquiring an additional 63,246 shares during the period. Finally, Quantinno Capital Management LP bought a new position in shares of Certara in the fourth quarter valued at approximately $1,565,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Stephens reiterated an "overweight" rating and set a $17.00 price target on shares of Certara in a research report on Thursday, February 27th. JMP Securities restated a "market perform" rating on shares of Certara in a report on Tuesday, May 6th. Barclays raised Certara from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $11.00 to $14.00 in a research note on Thursday, May 8th. Finally, TD Cowen began coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Certara has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Price Performance

Shares of NASDAQ:CERT traded up $0.01 on Monday, reaching $11.77. 1,263,783 shares of the company traded hands, compared to its average volume of 1,360,618. The stock has a market capitalization of $1.91 billion, a PE ratio of -58.85, a P/E/G ratio of 9.29 and a beta of 1.44. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company's 50 day moving average is $12.02 and its 200-day moving average is $11.86. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $16.93.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same period in the previous year, the firm earned $0.10 earnings per share. Certara's revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.